Every material Form 8-K Ingevity filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Ingevity announced that CFO Mary Dean Hall will leave her role effective May 1, 2026, and will advise the company for one year afterward. Phillip J. Platt, the current senior vice president of finance and chief accounting officer, will succeed her as CFO on the same date. The company also said Performance Chemicals president Richard White will depart on May 1, 2026, after moving to a special projects role on January 1, 2026. The filing contains no financial results, so the changes matter to shareholders mainly as a change in the finance leadership.
Mary Dean Hall's CFO role ends May 1, 2026; she will advise the company in an advisory capacity for one year.
Phillip J. Platt, age 44, who joined in 2015, is named SVP and CFO effective May 1, 2026. He is a certified public accountant.
Richard White, SVP and president of Performance Chemicals, moves to a special projects role January 1, 2026 and departs May 1, 2026.
Reid Clontz Jr. was appointed SVP, Operations, effective December 8, 2025.
Ingevity reported third-quarter 2025 results and revised its full-year 2025 guidance to total net sales of $1.25 billion to $1.35 billion and total adjusted EBITDA of $390 million to $405 million. The company said the revision reflects challenges in its Advanced Polymer Technologies segment, and it reported $43.5 million in net income, including discontinued operations, compared with a net loss of $107.2 million a year earlier.
Net sales from continuing operations were $333.1 million, flat compared with the prior year quarter.
Diluted EPS was $1.18 in the quarter, versus a diluted loss per share of $2.94 a year earlier; continuing operations diluted EPS was $1.10.
Full-year 2025 guidance: total net sales of $1.25 billion to $1.35 billion and total adjusted EBITDA of $390 million to $405 million.
The sale of most of the Industrial Specialties product line and the North Charleston crude tall oil refinery for $110 million is expected to close by early 2026.
Ingevity Corporation appointed Ruth Castillo as senior vice president and president of Performance Materials, its activated carbon segment, effective November 10, 2025. She will report directly to President and CEO Dave Li and join the executive leadership team. The filing does not include financial results, guidance, or compensation terms.
Appointment effective November 10, 2025; Castillo reports directly to CEO Dave Li
Castillo was vice president of global chemicals at Avantor from January 2025 to October 2025
Previously spent about 17 years at Celanese; has more than 25 years of industry experience
The filing does not describe compensation terms or include financial results
Ingevity agreed on September 3, 2025, to sell substantially all assets of its industrial specialties product line and its North Charleston crude tall oil refinery to Mainstream Pine Products for $110 million in cash, plus up to $19 million in contingent payments tied to future EBITDA. The company expects the deal to close by early 2026 and says it will reaffirm its full-year 2025 guidance, adjusted for reclassifying the sold assets as discontinued operations.
Cash purchase price of $110 million, subject to working capital adjustments, plus contingent consideration of $0 to $19 million
Ingevity expects 2025 revenue from the assets being sold to be about $130 million, with EBITDA margins in the low-to-mid single digits
Closing expected by early 2026; either party may terminate if the deal is not closed by January 31, 2026
Ingevity affirms 2025 guidance of sales of $1.25 billion to $1.40 billion and adjusted EBITDA of $390 million to $415 million, excluding the reclassification
Ingevity reported second quarter 2025 net sales of $365.1 million, down 7%, and a net loss of $146.5 million, or $4.02 per diluted share, which included a $183.8 million non-cash goodwill impairment tied to the Advanced Polymer Technologies segment. Adjusted earnings rose 39% to $51.1 million, and the company raised the low end of its full-year adjusted EBITDA guidance to a range of $390 million to $415 million while maintaining its sales guidance of $1.25 billion to $1.40 billion.
Q2 net sales were $365.1 million, down 7%, mainly due to lower Performance Chemicals sales
Net loss of $146.5 million and diluted loss of $4.02 per share, including a $183.8 million goodwill impairment
Adjusted earnings rose 39% to $51.1 million; diluted adjusted EPS was $1.39, up 38%
Full-year 2025 adjusted EBITDA guidance is $390 million to $415 million; sales guidance remains $1.25 billion to $1.40 billion
Ingevity said S. Edward Woodcock, executive vice president and president of Performance Materials, departed the company effective July 1, 2025, after a 37-year career. The company is searching for a successor, and Andrew Fox and Jonathan MacIver will manage the segment in the interim. Ingevity said it is not changing its previously disclosed full-year guidance.
Woodcock departed effective July 1, 2025 (Separation Date); the company will search for a successor.
Andrew Fox and Jonathan MacIver will manage the Performance Materials segment in the interim.
Severance includes a $500,000 lump sum under his October 1, 2024 incentive award and salary plus 2025 target incentive paid monthly over one year.
Full-year guidance is unchanged, according to the press release.
Ingevity reported first-quarter 2025 net sales of $284.0 million, down 17%, mainly due to repositioning of its Performance Chemicals segment. Net income was $20.5 million, or $0.56 per diluted share, compared with a net loss of $56.0 million a year earlier, and adjusted EBITDA rose 23% to $91.3 million. The company widened its full-year 2025 guidance to sales of $1.25 billion to $1.40 billion and adjusted EBITDA of $380 million to $415 million, citing lower auto production forecasts tied to trade tensions.
Q1 net sales were $284.0 million, down 17%, with Performance Chemicals sales down 35% to $95.0 million.
Net income was $20.5 million ($0.56 per diluted share) after $20.2 million in before-tax special charges; adjusted EPS was $0.99.
Adjusted EBITDA was $91.3 million, up 23%, with an adjusted EBITDA margin of 32.1%.
Full-year 2025 guidance: sales of $1.25 billion to $1.40 billion and adjusted EBITDA of $380 million to $415 million; no share repurchases were made in the quarter.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Ingevity filing is on SEC EDGAR ↗. 8-K briefs of other companies →